PriceTargets.com logo

Merus Labs International - MSL Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: C$0.00
  • Forecasted Upside: NaN
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
C$0.00 As of 07/20/2017 09:04 PM ET
+0 (0.00%)

This chart shows the closing price for MSL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Merus Labs International Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MSL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MSL

Analyst Price Target is C$0.00
This price target is based on 1 analysts offering 12 month price targets for Merus Labs International in the last 3 months. The average price target is C$0.00, with a high forecast of C$0.00 and a low forecast of C$10,000,000.00. The average price target represents a NaN upside from the last price of C$0.00.

This chart shows the closing price for MSL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 investment analysts is to buy stock in Merus Labs International.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/5/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/3/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/1/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/31/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
4/15/2024HC WainwrightReiterated RatingBuy
(Data available from 12/26/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/30/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/29/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/29/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/28/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/27/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/27/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/26/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/26/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Merus Labs International logo
Merus Labs International Inc. is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products. The Company's products include Elantan, Isoket, Deponit, Sintrom, Emselex/Enablex, Surgestone, Provames, Speciafoldine, Tredemine, Salagen, Estraderm MX and Vancocin. Elantan are tablets or capsules that belong to a group of medicines called organic nitrates. Isoket belongs to a group of medicines called organic nitrates. Deponit belongs to a group of medicines called nitrates. Sintrom is an anticoagulant indicated to treat and prevent thromboembolic diseases. Emselex/Enablex is used in adults to treat overactive bladder syndrome. Surgestone is used to treat women with menstrual irregularities due to ovulation disorder, dysmenorrhea and premenstrual syndrome. Provames is used as hormone replacement therapy in postmenopausal women with symptoms of estrogen deficiency.
Read More

Today's Range

Now: N/A

50 Day Range

MA: C$1.65
Low: C$1.65
High: C$1.65

52 Week Range

Now: N/A

Volume

21,975 shs

Average Volume

476,228 shs

Market Capitalization

C$193.64 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Merus Labs International?

The following Wall Street analysts have issued reports on Merus Labs International in the last year: HC Wainwright.
View the latest analyst ratings for MSL.

What is the current price target for Merus Labs International?

0 Wall Street analysts have set twelve-month price targets for Merus Labs International in the last year. has the lowest price target set, forecasting a price of C$10,000,000.00 for Merus Labs International in the next year.
View the latest price targets for MSL.

What is the current consensus analyst rating for Merus Labs International?

Merus Labs International currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MSL will outperform the market and that investors should add to their positions of Merus Labs International.
View the latest ratings for MSL.

What other companies compete with Merus Labs International?

Other companies that are similar to Merus Labs International include Westaim, Wall Financial, HIVE Digital Technologies, VersaBank and Points.com. Learn More about companies similar to Merus Labs International.

How do I contact Merus Labs International's investor relations team?

Merus Labs International's physical mailing address is 100 Wellington St. West Suite 2110 Stn Toronto Dom PO Box 151, TORONTO, ON M5K 1H1, Canada. The specialty pharmaceutical company's listed phone number is +1-905-7260995. The official website for Merus Labs International is www.meruslabs.com. Learn More about contacing Merus Labs International investor relations.